Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Neoplasms, Unknown Primary × ivosidenib × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 1

Conditions

Leukemia, Myeloid, Acute 7 Myelodysplastic Syndromes 3 Glioma 3 Wilms Tumor 2 Sarcoma, Ewing 2 Sarcoma 2 Rhabdomyosarcoma 2 Rhabdoid Tumor 2 Osteosarcoma 2 Neuroectodermal Tumors, Primitive, Peripheral 2 Neuroblastoma 2 Medulloblastoma 2 Lymphoma, Non-Hodgkin 2 Histiocytosis, Langerhans-Cell 2 Hepatoblastoma 2 Ependymoma 2 Xanthogranuloma, Juvenile 1 Neoplasms, Unknown Primary 1 Neoplasm Metastasis 1 Myeloproliferative Disorders 1 Lymphoma, Follicular 1 Histiocytic Sarcoma 1 Chondrosarcoma 1 Cholangiocarcinoma 1 Central Nervous System Neoplasms 1 Biliary Tract Neoplasms 1 AML 1

Interventions

Gemcitabine 8 Carboplatin 8 Paclitaxel 6 Capecitabine 4 Irinotecan 3 Bevacizumab 3 pembrolizumab 2 atezolizumab 2 Peripheral Blood Stem Cell Transplantation 2 Oxaliplatin 2 Filgrastim 2 Erlotinib Hydrochloride 2 Cisplatin 2 CP protocol 2 tegafur-gimeracil-oteracil 1 sintilimab 1 pertuzumab 1 pemigatinib 1 olaparib 1 ivosidenib 1 ipatasertib 1 etoposide phosphate 1 entrectinib 1 cobimetinib 1 belinostat 1 antineoplaston AS 2-1 1 antineoplaston A10 1 alectinib 1 Vemurafenib 1 Transurethral Resection of Prostate 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03498521 2025-11-19

CUPISCO

Hoffmann-La Roche

Phase 2 Completed

529 enrolled 16 charts

Neoplasms, Unknown Primary

Data powered by HemOnc (CC BY 4.0) Colophon ⚡